Masimo Co. (NASDAQ:MASI) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Masimo Co. (NASDAQ:MASI) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $194.80.

Several equities analysts have recently weighed in on MASI shares. Raymond James lifted their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Piper Sandler upped their price target on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday. Wells Fargo & Company raised their price objective on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday.

Masimo Stock Up 12.3 %

Masimo stock opened at $190.34 on Thursday. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $191.10. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The firm has a market capitalization of $10.19 billion, a price-to-earnings ratio of 131.27 and a beta of 1.02. The company’s 50 day simple moving average is $172.56 and its 200 day simple moving average is $152.84.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. As a group, sell-side analysts anticipate that Masimo will post 4.1 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MASI. FMR LLC increased its stake in Masimo by 41.2% in the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after buying an additional 1,970,883 shares during the last quarter. Capital Research Global Investors increased its position in shares of Masimo by 80.5% in the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider’s stock valued at $405,807,000 after acquiring an additional 1,094,647 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Masimo by 119.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock worth $286,823,000 after acquiring an additional 943,001 shares in the last quarter. Alliancebernstein L.P. boosted its position in Masimo by 1,276.9% during the fourth quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider’s stock valued at $156,604,000 after purchasing an additional 878,587 shares during the last quarter. Finally, Corient Private Wealth LLC grew its stake in Masimo by 8,847.1% in the fourth quarter. Corient Private Wealth LLC now owns 347,683 shares of the medical equipment provider’s stock valued at $57,472,000 after purchasing an additional 343,797 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.